Methamphetamine induces long-term changes in GABAA receptor α2 subunit and GAD67 expression

Biochemical and Biophysical Research Communications

Volumn 351, Issue 1, 2006, Pages 300-305

  Zhang, Xiuwu ^a   Lee, Tong H ^a   Xiong, Xueying ^a   Chen, Qiang ^a   Davidson, Colin ^a   Wetsel, William C ^a   Ellinwood, Everett H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Caudate; Dopamine; GABA; GAD67; GFAP; Glutamate; Methamphetamine; Neurotoxicity; Nucleus accumbens; Sensitization

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BRAIN PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE DECARBOXYLASE 67; METHAMPHETAMINE;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG MEGADOSE; GABAERGIC TRANSMISSION; INFUSION; MALE; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSITIZATION; UPREGULATION; WESTERN BLOTTING;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BRAIN; GENE EXPRESSION; GLUTAMATE DECARBOXYLASE; ISOENZYMES; MALE; METHAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A;

EID: 33750306687     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.10.046     Document Type: Article

References (42)

1. Bartoletti M., Gubellini C., Ricci F., and Gaiardi M. Baclofen blocks the development of sensitization to the locomotor stimulant effect of amphetamine. Behav. Pharmacol. 16 (2005) 553-558
2. Roberts D.C. Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction. Physiol. Behav. 86 (2005) 18-20
3. Ikemoto S. The supramammillary nucleus mediates primary reinforcement via GABA(A) receptors. Neuropsychopharmacology 30 (2005) 1088-1095
4. Caligiuri M.P., and Buitenhuys C. Do preclinical findings of methamphetamine-induced motor abnormalities translates to an observable clinical phenotype?. Neuropsychopharmacology 30 (2005) 2125-2134
5. Mark K.A., Soghomonian J.J., and Yamamoto B.K. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J. Neurosci. 24 (2004) 11449-11456
6. Floran B., Floran L., Sierra A., and Aceves J. D2 receptor-mediated inhibition of GABA release by endogenous dopamine in the rat globus pallidus. Neurosci. Lett. 237 (1997) 1-4
7. Kubota Y., Ito C., Sakurai E., Sakurai E., Watanabe T., and Ohtsu H. Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice. J. Neurochem. 83 (2002) 837-845
8. Barnard E.A., Skolnick P., Olsen R.W., Mohler H., Sieghart W., Biggio G., Braestrup C., Bateson A.N., and Langer S.Z. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acid A receptors: classification on the basis of subunit structure and receptor function. Pharmacol. Rev. 50 (1998) 291-313
9. Bowery N.G., Bettler B., Froestl W., Gallagher J.P., Marshall F., Raiteri M., Bonner T.I., and Enna S.J. International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid (B) receptors: structure and function. Pharmacol. Rev. 54 (2002) 247-264
10. Fritschy J.M., and Brunig I. Formation and plasticity of GABAergic synapses: physiological mechanisms and pathophysiological implications. Pharmacol. Ther. 98 (2003) 299-323
11. Luscher B., and Keller C.A. Regulation of GABAA receptor trafficking, channel activity, and functional plasticity of inhibitory synapses. Pharmacol. Ther. 102 (2004) 195-221
12. Whiting P.J. The GABA-A receptor gene family: new targets for therapeutic intervention. Neurochem. Int. 34 (1999) 387-390
13. Bormann J. The 'ABC' of GABA receptors. Trends Pharmacol. Sci. 21 (2000) 16-19
14. Brunig I., Suter A., Knuesel I., Luscher B., and Fritschy J.M. GABAergic terminals are required for postsynaptic clustering of dystrophin but not of GABA(A) receptors and gephyrin. J. Neurosci. 22 (2002) 4805-4813
15. Fehr C., Sander T., Tadic A., Lenzen K.P., Anghelescu I., Klawe C., Dahmen N., Schmidt L.G., and Szegedi A. Confirmation of association of the GABRA2 gene with alcohol dependence by subtype-specific analysis. Psychiatr. Genet. 16 (2006) 9-17
16. Lindefors N. Dopaminergic regulation of glutamic acid decarboxylase mRNA expression and GABA release in the striatum: a review. Prog. Neuropsychopharmacol. Biol. Psychiatry 17 (1993) 887-903
17. Soghomonian J.J., and Martin D.L. Two isoforms of glutamate decarboxylase: why?. Trends Pharmacol. Sci. 19 (1998) 500-505
18. Asada H., Kawamura Y., Maruyama K., Kume H., Ding R., Ji F.Y., Kanbara N., Kuzume H., Sanbo M., Yagi T., and Obata K. Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures. Biochem. Biophys. Res. Commun. 229 (1996) 891-895
19. Asad H., Kawamura Y., Maruyama K., Kume H., Ding R.G., Kanbara N., Kuzume H., Sanbo M., Yagi T., and Obata K. Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc. Natl. Acad. Sci. USA 94 (1997) 6496-6499
20. Ji F., and Obata K. Development of the GABA system in organotypic culture of hippocampal and cerebellar slices from a 67-kDa isoform of glutamic acid decarboxylase (GAD67)-deficient mice. Neurosci. Res. 33 (1999) 233-237
21. Ellinwood E.H., and Balster R.L. Rating the behavioral effects of amphetamine. Eur. J. Pharmacol. 28 (1974) 35-41
22. Zhang X., Mi J., Wetsel W.C., Davidson C., Xiong X., Chen Q., Ellinwood E.H., and Lee T.H. PI3 kinase is involved in cocaine behavioral sensitization and its reversal with brain area specificity. Biochem. Biophys. Res. Commun. 340 (2006) 1144-1150
23. Kalkman H.O., and Loetscher E. GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis. J. Neural Transm. 110 (2003) 803-812
24. Pekny M., and Nilsson M. Astrocyte activation and reactive gliosis. Glia 50 (2005) 427-434
25. Thomas D.M., Dowgiert J., Geddes T.J., Francescutti-Verbeem D., Liu X., and Kuhn D.M. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci. Lett. 367 (2004) 349-354
26. Weissman B.A., Brandeis R., Gilat E., Cohen G., Alkalay D., Rabinovitz I., Sonego H., and Raveh L. Monitoring drug-induced neurodegeneration by imaging of peripheral benzodiazepine receptors. Ann. N Y Acad. Sci. 1025 (2004) 584-589
27. Segovia G., and Mora F. Dopamine and GABA increases produced by activation of glutamate receptors in the nucleus accumbens are decreased during aging. Neurobiol. Aging 26 (2005) 91-101
28. McFarland K., Lapish C.C., and Kalivas P.W. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J. Neurosci. 23 (2003) 3531-3537
29. Tarazi F.I., and Baldessarini R.J. Regional localization of dopamine and ionotropic glutamate receptor subtypes in striatolimbic brain regions. J. Neurosci. Res. 55 (1999) 401-410
30. Segovia G., and Mora F. Involvement of NMDA and AMPA/kainate receptors in the effects of endogenous glutamate on extracellular concentrations of dopamine and GABA in the nucleus accumbens of the awake rat. Brain Res. Bull. 54 (2001) 153-157
31. Self D.W. Regulation of drug-taking and -seeking behaviors by neuroadaptations in the mesolimbic dopamine system. Neuropharmacology 47 Suppl. 1 (2004) 242-255
32. Heimer L. A new anatomical framework for neuropsychiatric disorders and drug abuse. Am. J. Psychiatry 160 (2003) 1726-1739
33. Liu Q.S., Pu L., and Poo M.M. Repeated cocaine exposure in vivo facilitates LTP induction in midbrain dopamine neurons. Nature 437 (2005) 1027-1031
34. Jayaram P., and Steketee J.D. Cocaine-induced increases in medial prefrontal cortical GABA transmission involves glutamatergic receptors. Eur. J. Pharmacol. 531 (2006) 74-79
35. Johnson-Davis K.L., Hanson G.R., and Keefe K.A. Long-term post-synaptic consequences of methamphetamine on preprotachykinin mRNA expression. J. Neurochem. 82 (2002) 1472-1479
36. Bustamante D., You Z.B., Castel M.N., Johansson S., Goiny M., and Terenius L. Effect of single and repeated methamphetamine treatment on neurotransmitter release in the substantia nigra and neostriatum in the rat. J. Neurochem. 83 (2002) 645-654
37. Kamata K., and Kameyama T. Effect of chronic administration of methamphetamine on responsiveness of substantia nigra zona reticulate neurons to GABA or a GABA agonist in rats. Arch. Pharmacol. 334 (1986) 458-462
38. Misgeld U. Innervation of the substantia nigra. Cell Tissue Res. 318 (2004) 107-114
39. Aceves J., Floran B., Sierra A., and Mariscal S. D-1 receptor mediated modulation of the release of gamma-aminobutyric acid by endogenous dopamine in the basal ganglia of the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 19 (1995) 727-739
40. Nicholson L.F., Faull R.L., Waldvogel H.J., and Dragunow M. GABA and GABAA receptor changes in the substantia nigra of the rat following quinolinic acid lesions in the striatum closely resemble Huntington's disease. Neuroscience 66 (1995) 507-521
41. Timmerman W., and Westerink B.H. Electrical stimulation of the substantia nigra reticulata: detection of neuronal extracellular GABA in the ventromedial thalamus and its regulatory mechanism using microdialysis in awake rats. Synapse 26 (1997) 62-71
42. Altar C.A., and Hauser K. Topography of substantia nigra innervation by D1 receptor-containing striatal neurons. Brain Res. 410 (1987) 1-11